To encourage citizens to undergo screening for colorectal cancer, the city of Nîmes, France, has launched an awareness campaign titled “Il est temps de monter sur le trône” — “It’s Time to Get on the Throne.” This initiative is part of a broader effort to promote early detection and prevention of the disease. We delve into the details with Dr. Stéphane Obled, a gastroenterologist and digestive oncologist practicing at the Nîmes University Hospital, to provide a comprehensive understanding of the campaign and its significance.[2]March, often referred to as “March Bleu” in France, is the designated month for colorectal cancer awareness. Throughout March, various actions are organized by the city to motivate residents to get tested. Even though there has been a slight increase in screening rates in the Gard region, rising by 10% between 2022 and 2023, healthcare professionals stress that these efforts are still insufficient.

Dr. Obled emphasized the importance of screening, “Detected early enough, this cancer is treated very well, it can be healed in 90% of cases.” Colorectal cancer is a prevalent disease, affecting more than 48,000 people annually in France and resulting in 17,000 deaths each year. It is the third most common cancer in men (after prostate and lung) and the second most common in women (after breast cancer).

From the French National Institute of Cancer (INCA): Taken from Institut National du Cancer (INCA)’s 2023 report:
Early detection of colorectal cancer can save lives. Early screening and tests make it is imperative
INCA Differences by geography, 2023

The campaign specifically targets individuals aged 50 to 74, encouraging them to undergo screening tests. These tests are crucial because colorectal cancer can often develop without symptoms, making early detection through screening the most effective way to identify and treat the disease.

Nîmes is not alone in its efforts. Globally, including in the U.S., colorectal cancer awareness campaigns have been gaining momentum. For instance, the American Cancer Society (ACS) and the Centers for Disease Control and Prevention (CDC) have been championing similar initiatives to raise awareness and encourage screening. Despite these efforts, both France and the U.S. face challenges in achieving sufficient screening rates. While ACS has attributed progression to comprehensive screening efforts and research, 90% recovery rates suggests early detection remains under-supported even in the US. The challenges persist primarily due to lack of awareness and reluctance among individuals to undergo screening tests.

In addressing some of the counterarguments, experts note that while early detection and screening are crucial, they are not without their costs and potential discomforts. However, the benefits of early detection far outweigh these concerns. “It can be difficult to refrain from avoiding invasive tests that seem unnecessarily stressful, time-consuming, and scary” says Dr. Obled regarding reluctance. Between the East and West coasts, nations have equally struggled to shift patient behavior and perspectives. Time costs for some can extend well into off-hours and lost wages. Despite these challenges, the success stories of those who have benefited from early detection provide compelling evidence for the importance of regular screening.

Recent Developments and Practical Applications

Recent advancements in screening technologies, such as stool-based tests, colonoscopies, and other non-invasive methods, have made the process more convenient and less frightening. These tests can sometimes be conducted at home, providing a higher level of comfort and privacy for individuals.

For a deeper dive into the practical applications of these technologies, Dr. Obled provides an example, “Recent advances in flexible sigmoidoscopy and colonoscopy have made potential cancer screening both comfortable and analytic.”
Techniques have also shifted imbalanced weight towards health communicators, shifting stigma from medical reticence with non-species tested attempts to screen potential or high risk individuals. ”
An infuriating misunderstanding in screening is a similar sentiment found towards these practices within less informed demographics who find cost a deterring factor, resulting in billions of dollars spent on preventable diseases reaching late-stage conditions. A recent shift from pre-taxed health services to increasingly incentivized health care reimbursements.

However, it should not take an omnibus budget for politicians to see the immense economic and humane value in early detection rather than late-stage morbidity. Costs and procedures can vary from patient to patient while full coverage caps at $2,000 for thorough diagnostics and anywhere from $1,200 to $4,000 for full-suite preventative procedures. Cancer screening advocacy work is unending, but increasing awareness and advocacy for early testing and screening is imperative to stay ahead of preventable diseases, regardless of economic status

Case Study: Success Stories

A notable case study from Europe shows how early detection saved a life. Gaston, a 65-year-old resident of Nantes, had always been wary of screening tests. However, after his wife’s persistent encouragement, he decided to undergo a colonoscopy. The test revealed early-stage colorectal cancer, which was successfully treated, and Gaston is now cancer-free.

Gaston’s story highlights the importance of regular screening and the life-saving potential of early detection.

Colorectal cancer screening remains a critical component in the fight against this deadly disease. Campaigns like “It’s Time to Get on the Throne” in Nîmes, coupled with ongoing awareness efforts, are instrumental in driving home the message of early detection and prevention. In the broader discussion of colorectal cancer, emphasizing key points and addressing potential concerns with robust evidence and case studies can significantly enhance awareness and promote healthier practices.